As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Avenue Therapeutics, Inc. The largest reported stake is Fortress Biotech, Inc.'s, at 13.4%. 2 filings are on record since January 6, 2026 (Schedule 13D/A, January 6, 2026).
Sell to companies like Avenue Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Avenue Therapeutics, Inc. has 2 Schedule 13D or 13G filings on record since 2026-01-06. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fortress Biotech, Inc. | 13.4% | 439,955 | SCHEDULE 13D/A, 2026-01-06 | 2026-01-02 |
| Ikarian Capital, LLC | 4.1% | 130,820 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Avenue Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Avenue Therapeutics, Inc. and the records around it.
Companies that share a holder
- Fortress Biotech, Inc. also filed stake reports on 1 other company: Mustang Bio, Inc. (Jan 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
Watch Avenue Therapeutics, Inc.
Get an email when Avenue Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avenue Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Avenue Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avenue Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. | 439,955 | 0 | 439,659 | 296 | SCHEDULE 13D/A, 2026-01-06 |
| Ikarian Capital, LLC | 0 | 130,820 | 0 | 130,820 | SCHEDULE 13G/A, 2026-02-17 |
| Neil Shahrestani | 0 | 130,820 | 0 | 130,820 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing names Avenue Therapeutics, Inc., with its principal executive office as 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 (SCHEDULE 13G/A, 2026-02-17).
Source of funds (Item 3)
The Reporting Person is filing this Schedule 13D as a result of the issuance by the Issuer of: 111,209 shares of the Issuer's common stock as an Annual Equity Grant under the Founders Agreement (defined below).Fortress Biotech, Inc., SCHEDULE 13D/A, 2026-01-06
Purpose of Transaction (Item 4)
Fortress Biotech, Inc.
The Reporting Person is party to that certain Second Amended and Restated Founders Agreement with the Issuer (as amended, the "Founders Agreement"), in connection with the Issuer's formation. Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation (as amended, the "Charter"), the Issuer issues annually to the Reporting Person shares of common stock equal to two and one-half percent (2.5%) of the fully-diluted outstanding equity of the Issuer, as measured as of the date of such issuance (the "Annual Equity Grant"). The foregoing description of the Charter and Founders Agreement are qualified in its entirety by reference to the full text of the Charter and Founders Agreement which are incorporated herein by reference as Exhibits 7.01 and 7.03.Item 4 of the SCHEDULE 13D/A filed 2026-01-06
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-06 | Fortress Biotech, Inc. | 13.4% | SCHEDULE 13D/A |
| 2026-02-17 | Ikarian Capital, LLC | 4.1% | SCHEDULE 13G/A |
Questions about who owns Avenue Therapeutics, Inc.
Who owns Avenue Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Avenue Therapeutics, Inc.: Fortress Biotech, Inc. (13.4%, Schedule 13D/A, filed 2026-01-06).
When did Fortress Biotech, Inc. buy into Avenue Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fortress Biotech, Inc. on this page is the Schedule 13D/A, filed 2026-01-06, reporting 13.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Avenue Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.